Over the past year, we’ve designed a process that is meant to mimic public package publishing as closely as possible, where packages are automatically assessed by a series of checks which may prompt manual revision should the automated processing …
Increasingly biostatisticians in pharma companies would like to use R on a daily basis, e.g. the growing number of participants in R/Pharma conferences is one metric showing this trend. As R programs replace proprietary software in this regulated …
In recent years late stage Pharma has begun to transition from a consumer of open source, and a sporadic creator, to a heavily invested collaborator on open source tools like R packages. In this short talk, James will discuss our recent focus on open …
In this short talk I will present few packages that can be used inside package testing framework that will help to increase overall quality of a package. The main point of focus would be static R code analysis tools such as well-known codetools …
R package validation is in all our minds since the pharmaceutical industry started moving away from SAS to R for its statistical analysis and regulatory submissions. Opting for open source programming requires to revisit our way of validating code, …
R and Biocondutor are important tools supporting scientific workflows across early Research and Development at Roche/Genentech. We have a broad R users community, which includes Data Scientists, Software Developers and consumers of Data Products …
MMRMs are often used as the primary analysis of continuous endpoints in longitudinal clinical trials (see e.g. Mallinckrod et al, 2008). Essentially, an MMRM is a specific linear mixed effects model that includes (at least) an interaction of …